Principal Financial Group Inc. increased its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 13.7% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 281,556 shares of the life sciences company’s stock after purchasing an additional 33,918 shares during the quarter. Principal Financial Group Inc.’s holdings in Integra LifeSciences were worth $15,212,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Steward Partners Investment Advisory LLC grew its stake in Integra LifeSciences by 73.7% in the first quarter. Steward Partners Investment Advisory LLC now owns 707 shares of the life sciences company’s stock valued at $45,000 after purchasing an additional 300 shares in the last quarter. First Horizon Advisors Inc. purchased a new position in Integra LifeSciences in the second quarter valued at about $54,000. Covestor Ltd grew its stake in Integra LifeSciences by 63.0% in the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after purchasing an additional 602 shares in the last quarter. Captrust Financial Advisors grew its stake in Integra LifeSciences by 95.0% in the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after purchasing an additional 976 shares in the last quarter. Finally, Parametrica Management Ltd purchased a new position in Integra LifeSciences in the first quarter valued at about $215,000. Hedge funds and other institutional investors own 87.33% of the company’s stock.
Integra LifeSciences Price Performance
NASDAQ IART opened at $53.69 on Friday. Integra LifeSciences Holdings Co. has a twelve month low of $40.67 and a twelve month high of $69.95. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.91 and a current ratio of 3.93. The stock has a market capitalization of $4.48 billion, a PE ratio of 26.06, a P/E/G ratio of 1.61 and a beta of 1.17. The stock has a 50-day simple moving average of $46.92 and a 200 day simple moving average of $52.23.
Wall Street Analyst Weigh In
About Integra LifeSciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.